Cover Image
Market Research Report

Partnerships, Licensing, Investments and M&A Deals and Trends for September 2016 in Pharmaceuticals

Published by GlobalData Product code 248823
Published Content info 101 Pages
Immediate Delivery Available
Price
Back to Top
Partnerships, Licensing, Investments and M&A Deals and Trends for September 2016 in Pharmaceuticals
Published: November 1, 2016 Content info: 101 Pages
Description

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for September 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in September 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents
Product Code: GDPH0502MD

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Pharmaceuticals & Healthcare, Global, Deal Summary,

  • 2.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, September 2016
  • 2.2. Pharmaceuticals & Healthcare, Global, Major Deals, September 2016
    • 2.2.1. Shire Raises USD12.1 Billion in Public Offering of Notes
    • 2.2.2. Gilead Sciences Raises USD5 Billion in Public Offering of Notes
    • 2.2.3. Johnson & Johnson to Acquire Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion
    • 2.2.4. Sanofi Prices Public Offering of Notes for USD3.3 Billion
    • 2.2.5. Allergan to Acquire Tobira Therapeutics in Tender Offer
  • 2.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, September 2016
  • 2.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, September 2016

3. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type

  • 3.1. Pharmaceuticals & Healthcare, Global, M&A, September 2016
    • 3.1.1. Top M&A Deals in September 2016
    • 3.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, April 2016-September 2016
  • 3.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, September 2016
    • 3.2.1. Top Equity Offering Deals in September 2016
    • 3.2.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, April 2016-September 2016
  • 3.3. Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, September 2016
    • 3.3.1. Top PE/VC Deals in September 2016
    • 3.3.2. Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, September 2016
    • 3.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, September 2016
    • 3.3.4. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, April 2016-September 2016
    • 3.3.5. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2016-September 2016
  • 3.4. Pharmaceuticals & Healthcare, Global, Partnership Deals, September 2016
  • 3.5. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, April 2016-September 2016
  • 3.6. Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), September 2016
    • 3.6.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, September 2016
  • 3.7. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2016-September 2016
  • 3.8. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, April 2016-September 2016
  • 3.9. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), April 2016-September 2016
  • 3.10. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2016-September 2016

4. Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2016

  • 4.1. Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2016
  • 4.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2016
  • 4.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), April 2016-September 2016
  • 4.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), April 2016-September 2016
  • 4.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), April 2016-September 2016
  • 4.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), April 2016-September 2016
    • 4.6.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, September 2016
    • 4.6.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, September 2016
    • 4.6.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, September 2016

5. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

  • 5.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, September 2016
    • 5.1.1. Oncology-Deals of the Month
  • 5.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, September 2016
    • 5.2.1. Central Nervous System-Deals of the Month
  • 5.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, September 2016
    • 5.3.1. Infectious Diseases-Deals of the Month
  • 5.4. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, September 2016
    • 5.4.1. Cardiovascular-Deals of the Month
  • 5.5. Pharmaceuticals & Healthcare, Global, Immunology Deals, September 2016
    • 5.5.1. Immunology-Deals of the Month
  • 5.6. Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, September 2016
    • 5.6.1. Gastrointestinal-Deal of the Month
  • 5.7. Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, September 2016
    • 5.7.1. Metabolic Disorders-Deal of the Month

6. Deal Summary by Geography

  • 6.1. Pharmaceuticals & Healthcare, North America Deals, September 2016
    • 6.1.1. North America-Deals of the Month
  • 6.2. Pharmaceuticals & Healthcare, Europe, Deals, September 2016
    • 6.2.1. Europe-Deals of the Month
  • 6.3. Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, September 2016
    • 6.3.1. Asia-Pacific-Deals of the Month
  • 6.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, September 2016
    • 6.4.1. Rest of the World-Deals of the Month

7. Pharmaceuticals & Healthcare, Global, Top Financial Advisors

  • 7.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, April 2016-September 2016
  • 7.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, April 2016-September 2016

8. Further Information

  • 8.1. Methodology
  • 8.2. About GlobalData
  • 8.3. Disclosure information
  • 8.4. Disclaimer

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, September 2016
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), September 2016
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, September 2016
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2016 - September 2016
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, September 2016
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, September 2016
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, April 2016 - September 2016
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), September 2016
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2016 - September 2016
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), September 2016
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2016 - September 2016
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), April 2016 - September 2016
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016
  • Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), September 2016
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2016 - September 2016
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2016
  • Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, September 2016
  • Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, September 2016
  • Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, September 2016
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2016 - September 2016

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), September 2016
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), September 2016
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2016 - September 2016
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2016 - September 2016
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), September 2016
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), September 2016
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2016 - September 2016
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2016 - September 2016
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2016 - September 2016
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 - September 2016
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, April 2016 - September 2016
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), April 2016 - September 2016
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), September 2016
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2016 - September 2016
Back to Top